Want to see FR:AELIS full AI Analyst Report?
AELIS Stock Chart & Stats
€1.15
€0.07(3.63%)
At close: 4:00 PM EST
€1.15
€0.07(3.63%)
Day’s Range― - ―
52-Week Range€0.67 - €2.30
Previous CloseN/A
Volume1.12K
Average Volume (3M)48.51K
Market Cap
€14.25M
Enterprise Value€12.87M
Total Cash (Recent Filing)€8.21M
Total Debt (Recent Filing)€6.60M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding13,706,586
10 Day Avg. Volume44,132
30 Day Avg. Volume48,508
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.49
Price to Sales (P/S)7.43
P/FCF Ratio-2.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)€12.40M
Bulls Say, Bears Say
Bulls Say
Focused CNS R&D And Novel TherapeuticsAelis Farma's clear, durable focus on small‑molecule therapeutics for CNS and related disorders creates a concentrated R&D thesis. Specialization can produce high-value, hard-to-replicate assets and makes the company a logical partner or acquisition target if clinical progress continues, supporting long-term strategic optionality.
Reduced Operating Cash Burn In 2025The material reduction in operating cash outflows in 2025 versus 2024 indicates improving cost discipline or program prioritization. Sustained lower cash burn extends runway and reduces near‑term financing pressure, improving the company's ability to advance clinical programs without immediate dilutive capital raises.
Partnering-focused Business ModelA business model centered on research, development and partnering is structurally capital‑efficient for clinical-stage biotech. It allows the firm to de‑risk programs via collaborations, access non‑dilutive or milestone funding, and avoid building costly commercial infrastructure until late‑stage validation.
Bears Say
Persistent Multi-year Losses And Negative MarginsSustained, widening operating and net losses materially erode capital and are not offset by revenue. Without successful clinical readouts or partnering, these losses indicate the company cannot self‑fund growth, constrain strategic choices, and increase the probability of repeated financing that dilutes shareholders and pressures management priorities.
Weak Cash Generation And Reliance On External FundingPersistent negative operating and free cash flow signal structural cash generation weakness. The company will likely need recurrent capital infusions to sustain R&D, increasing dilution and execution risk. Reliance on external funding also makes progress contingent on capital market access and partner appetite.
Eroding Equity And Limited Capital CushionA shrinking equity base alongside rising debt reduces the balance sheet buffer against setbacks. Lower capital cushion limits borrowing capacity, heightens refinancing and covenant risk, and increases the likelihood of dilutive recapitalizations, constraining long‑term strategic flexibility and partner negotiations.
Aelis Farma SA News
AELIS FAQ
What was Aelis Farma SA’s price range in the past 12 months?
Aelis Farma SA lowest stock price was €0.67 and its highest was €2.30 in the past 12 months.
What is Aelis Farma SA’s market cap?
Aelis Farma SA’s market cap is €14.25M.
When is Aelis Farma SA’s upcoming earnings report date?
Aelis Farma SA’s upcoming earnings report date is Sep 15, 2026 which is in 72 days.
How were Aelis Farma SA’s earnings last quarter?
Aelis Farma SA released its earnings results on Mar 30, 2026. The company reported -€0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.154.
Is Aelis Farma SA overvalued?
According to Wall Street analysts Aelis Farma SA’s price is currently Overvalued.
Does Aelis Farma SA pay dividends?
Aelis Farma SA does not currently pay dividends.
What is Aelis Farma SA’s EPS estimate?
Aelis Farma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aelis Farma SA have?
Aelis Farma SA has 13,706,586 shares outstanding.
What happened to Aelis Farma SA’s price movement after its last earnings report?
Aelis Farma SA reported an EPS of -€0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.575%.
Which hedge fund is a major shareholder of Aelis Farma SA?
Currently, no hedge funds are holding shares in FR:AELIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aelis Farma SA
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
Technical Analysis
Poxel SA
―
GenSight Biologics SA
―
Advicenne SA
―
Biophytis SA
―
NFL Biosciences SA
―